We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
- Authors
Koyama, S.; Fujisawa, S.; Watanabe, R.; Itabashi, M.; Ishibashi, D.; Ishii, Y.; Hattori, Y.; Nakajima, Y.; Motohashi, K.; Takasaki, H.; Kawasaki, R.; Hashimoto, C.; Yamazaki, E.; Koharazawa, H.; Takemura, S.; Tomita, N.; Sakai, R.; Motomura, S.; Nakajima, H.
- Abstract
Introduction The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma ( PTCL) remains unknown. Methods We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011. Results The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). The subtypes of PTCL were 39 PTCL, not otherwise specified and 39 angioimmunoblastic T-cell lymphoma ( AITL). The median observation period for the surviving patients was 50 months. The overall survival ( OS) was poorer in patients with serum ferritin level above the upper normal limit ( n = 28), compared with patients with serum ferritin level within normal range ( n = 50; 4-year OS: 23% vs. 72%; P < 0.001). In the multivariate analysis, poor performance status ( P = 0.006) and elevated serum ferritin level ( P = 0.018) were independent risk factors for poor OS. Conclusion Serum ferritin level is a useful prognostic marker for PTCL.
- Subjects
ANTHRACYCLINES; BIOMARKERS; CANCER patients; CANCER patient medical care; FERRITIN; PROBABILITY theory; REFERENCE values; SURVIVAL analysis (Biometry); RETROSPECTIVE studies; DESCRIPTIVE statistics; T-cell lymphoma; PROGNOSIS; THERAPEUTICS
- Publication
International Journal of Laboratory Hematology, 2017, Vol 39, Issue 1, p112
- ISSN
1751-5521
- Publication type
Article
- DOI
10.1111/ijlh.12592